Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tislelizumab plus anlotinib as maintenance therapy for extensive stage small cell lung cancer is ongoing with status currently unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN